Short answer
Compass Therapeutics, Inc. (CMPX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Compass Therapeutics’ quarter and nine months ended September 30, 2026.
Compass Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Compass Therapeutics’ quarter and nine months ended September 30, 2026
- Financial results and management commentary are contained in Exhibit 99.1, relevant for assessing operating performance and cash position
Item EX-99.1 · Exhibit EX-99.1
- Q3 net loss $27.2M, or $0.15 per share, versus $14.3M, or $0.08, as pipeline investment accelerated
- Cash and marketable securities $163M, down from $209M at December 31, 2025, funding operations into 2028
- Tovecimig BLA preparations continue despite FDA recommendation for an additional survival-benefit study, creating a key regulatory risk
- COMPANION-002 showed ORR 18.0% versus 5.3% and median PFS 4.7 versus 2.6 months, but crossover-adjusted OS was not statistically significant
- CTX-8371 and CTX-10726 remain clinical catalysts, with study updates expected later in 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Compass Therapeutics, Inc. 8-K filings
Get the next CMPX 8-K as it lands
Follow CMPX for push alerts, or ask the research agent what this filing means.